The Biologics News and Reports Portal

Show Cart

TCR T-Cells and Antibodies

Results 11 - 16 of 16

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

3,000.00 €

4,500.00 €

(Discount: 33.33%)

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

2,450.00 €

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

2,050.00 €

Mar 2015 Engineered TCR and CAR Immunotherapeutics 2015

1,960.00 €

2,450.00 €

(Discount: 20.00%)

Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

1,450.00 €

Dec 2012 Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists

700.00 €

Start
Prev
1
2
Next
End

Currencies

Shopping cart

Cart empty

Currencies

Shopping cart

Cart empty

Latest report

Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-β, CXCR4, CSF-1R, CD47-SIRPα, adenosine pathway & STING 2018

Featured Products

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

TCR T-Cells and Antibodies

Sep 2016 Report package: T-Cell Immunotherapy by bispecific antibodies and CAR & TCR engineered T-cells

Aug 2016 TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs

May 2016 T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Mar 2015 Engineered TCR and CAR Immunotherapeutics 2015

Oct 2013 The Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells: Emerging Opportunities for the Biopharmaceutical Industry

Dec 2012 Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists

Currencies

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Currencies

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing